DK1765793T3 - Anacetrapib og andre cetp-inhibitorer - Google Patents

Anacetrapib og andre cetp-inhibitorer

Info

Publication number: DK1765793T3
Authority: DK; Denmark
Prior art keywords: anacetrapib; cetp inhibitors; cetp; inhibitors
Prior art date: 2004-07-02

Application number

DK05771445.3T

Other languages

English (en)

Inventor

Amjad Ali

Joann M Napolitano

Qiaolin Deng

Zhijian Lu

Peter J Sinclair

Gayle E Taylor

Christopher F Thompson

Nazia Quraishi

Cameron J Smith

Julianne A Hunt

Adrian A Dowst

Yi-Heng Chen

Hong Li

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-02

Filing date

2005-07-01

Publication date

2013-01-14

2005-07-01 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2013-01-14 Application granted granted Critical

2013-01-14 Publication of DK1765793T3 publication Critical patent/DK1765793T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrrole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Cephalosporin Compounds (AREA)
Enzymes And Modification Thereof (AREA)

DK05771445.3T 2004-07-02 2005-07-01 Anacetrapib og andre cetp-inhibitorer DK1765793T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US58527404P	2004-07-02	2004-07-02
US64610305P	2005-01-21	2005-01-21
PCT/US2005/023775 WO2006014413A1 (en)	2004-07-02	2005-07-01	Cetp inhibitors

Publications (1)

Publication Number	Publication Date
DK1765793T3 true DK1765793T3 (da)	2013-01-14

Family

ID=35045145

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05771445.3T DK1765793T3 (da)	2004-07-02	2005-07-01	Anacetrapib og andre cetp-inhibitorer

Country Status (37)

Country	Link
US (5)	US7652049B2 (da)
EP (2)	EP2415759A1 (da)
JP (3)	JP4695139B2 (da)
KR (1)	KR101204336B1 (da)
CN (4)	CN104447603A (da)
AR (2)	AR049956A1 (da)
AU (1)	AU2005270058B2 (da)
BR (1)	BRPI0512910A (da)
CA (1)	CA2570717C (da)
CR (1)	CR8808A (da)
CY (1)	CY1117930T1 (da)
DK (1)	DK1765793T3 (da)
DO (1)	DOP2005000123A (da)
EA (1)	EA011130B1 (da)
EC (1)	ECSP067124A (da)
EG (1)	EG27138A (da)
ES (1)	ES2393721T3 (da)
GE (1)	GEP20094694B (da)
GT (1)	GT200500175A (da)
HR (1)	HRP20120993T1 (da)
IL (2)	IL180432A (da)
JO (1)	JO2994B1 (da)
MA (1)	MA28780B1 (da)
MX (1)	MX2007000035A (da)
MY (1)	MY167430A (da)
NI (1)	NI200600322A (da)
NO (1)	NO339808B1 (da)
NZ (1)	NZ552061A (da)
PA (1)	PA8638101A1 (da)
PE (1)	PE20060525A1 (da)
PL (1)	PL1765793T3 (da)
PT (1)	PT1765793E (da)
RS (1)	RS52563B (da)
SI (1)	SI1765793T1 (da)
SV (1)	SV2007002160A (da)
TW (1)	TWI299991B (da)
WO (2)	WO2006014413A1 (da)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7270971B2 (en) *	2003-10-16	2007-09-18	Merck & Co., Inc.	Fluorescence assay for measuring the rate of cholesterol ester transfer
DOP2005000123A (es) *	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
EP2985022B1 (en) *	2005-07-01	2018-09-12	Merck Sharp & Dohme Corp.	Process for synthesizing a cetp inhibitor
US8486983B2 (en)	2005-12-05	2013-07-16	Merck Sharp & Dohme Corp.	Self-emulsifying formulations of CETP inhibitors
TW200732313A (en) *	2005-12-15	2007-09-01	Astrazeneca Ab	Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
JP5040036B2 (ja)	2005-12-30	2012-10-03	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
JP5192392B2 (ja) *	2005-12-30	2013-05-08	メルク・シャープ・エンド・ドーム・コーポレイション	コレステリルエステル転送タンパク質阻害剤
US7910592B2 (en) *	2005-12-30	2011-03-22	Merck Sharp & Dohme Corp.	CETP inhibitors
JP5199121B2 (ja) *	2005-12-30	2013-05-15	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｅｔｐ阻害剤
JP5773560B2 (ja) *	2006-02-09	2015-09-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｅｔｐ阻害剤のポリマー製剤
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
WO2007136672A2 (en) *	2006-05-19	2007-11-29	Merck & Co., Inc.	Synthesis of a biaryl synthetic intermediate
WO2008082567A1 (en) *	2006-12-29	2008-07-10	Merck & Co., Inc.	Process for synthesizing a cetp inhibitor
EP2114971B1 (en)	2007-01-26	2015-06-17	Kaneq Pharma Inc.	Fused aromatic ptp-1b inhibitors
CA2681628C (en) *	2007-03-16	2016-10-18	Concert Pharmaceuticals, Inc.	Inhibitors of cholesterol ester transfer protein
EP2155187B1 (en)	2007-05-07	2016-05-25	Merck Sharp & Dohme Corp.	Method of treatment using fused aromatic compounds having anti-diabetic activity
EP3150589A1 (en)	2007-06-08	2017-04-05	MannKind Corporation	Ire-1a inhibitors
JP2010530417A (ja) *	2007-06-20	2010-09-09	メルク・シャープ・エンド・ドーム・コーポレイション	ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
AU2008266957A1 (en) *	2007-06-20	2008-12-24	Merck Sharp & Dohme Corp.	CETP inhibitors derived from benzoxazole arylamides
WO2008156715A1 (en) *	2007-06-20	2008-12-24	Merck & Co., Inc.	Cetp inhibitors derived from benzoxazole arylamides
BRPI0814403A2 (pt)	2007-07-02	2015-01-27	Hoffmann La Roche	Devirados de imidazol como antagonistas de receptor ccr2
JP5470557B2 (ja) *	2007-07-26	2014-04-16	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
AR069207A1 (es) *	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en)	2007-12-11	2009-06-18	Vitae Pharmaceuticals, Inc.	Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) *	2008-01-07	2009-08-16	Vitae Pharmaceuticals Inc	Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
CA2712500A1 (en) *	2008-01-24	2009-07-30	Vitae Pharmaceuticals, Inc.	Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US20110098352A1 (en) *	2008-02-01	2011-04-28	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CA2713139C (en) *	2008-02-01	2013-04-23	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CA2714532A1 (en) *	2008-02-11	2009-08-20	Vitae Pharmaceuticals, Inc.	1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
JP2011512359A (ja)	2008-02-14	2011-04-21	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
CA2715290A1 (en) *	2008-02-15	2009-08-20	Vitae Pharmaceuticals, Inc.	Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009108720A2 (en)	2008-02-25	2009-09-03	Amira Pharmaceuticals, Inc.	Antagonists of prostaglandin d2 receptors
JP5538356B2 (ja) *	2008-03-18	2014-07-02	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
US8426449B2 (en)	2008-04-02	2013-04-23	Panmira Pharmaceuticals, Llc	Aminoalkylphenyl antagonists of prostaglandin D2 receptors
EP2300461B1 (en)	2008-05-01	2013-04-17	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723039A1 (en)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8063088B2 (en) *	2008-06-11	2011-11-22	Hoffmann-La Roche Inc.	Imidazolidine derivatives
TW201016691A (en)	2008-07-25	2010-05-01	Boehringer Ingelheim Int	Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN102105454A (zh)	2008-07-25	2011-06-22	贝林格尔.英格海姆国际有限公司	合成1型11β-羟基类固醇脱氢酶的抑制剂
PL2324018T3 (pl)	2008-07-25	2014-02-28	Boehringer Ingelheim Int	Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
GB2463788B (en)	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
DE102008049675A1 (de)	2008-09-30	2010-04-01	Markus Dr. Heinrich	Verfahren zur Herstellung von 3-Aminobiphenylen
EP2348859B1 (en) *	2008-10-01	2013-12-04	Merck Sharp & Dohme Corp.	Prodrugs of oxazolidinone cetp inhibitors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
JP5575137B2 (ja)	2008-10-22	2014-08-20	メルク・シャープ・アンド・ドーム・コーポレーション	抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8383654B2 (en)	2008-11-17	2013-02-26	Panmira Pharmaceuticals, Llc	Heterocyclic antagonists of prostaglandin D2 receptors
TW201028414A (en)	2009-01-16	2010-08-01	Merck Sharp & Dohme	Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2010085525A1 (en)	2009-01-23	2010-07-29	Schering Corporation	Bridged and fused heterocyclic antidiabetic compounds
AU2010206789A1 (en)	2009-01-23	2011-07-28	Merck Sharp & Dohme Corp.	Bridged and fused antidiabetic compounds
WO2010089303A1 (en)	2009-02-04	2010-08-12	Boehringer Ingelheim International Gmbh	CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
TW201040186A (en)	2009-02-05	2010-11-16	Schering Corp	Phthalazine-containing antidiabetic compounds
UA109255C2 (ru)	2009-04-30	2015-08-10	Берінгер Інгельхайм Інтернешнл Гмбх	Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US8927539B2 (en)	2009-06-11	2015-01-06	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (en)	2009-07-01	2014-08-13	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8815917B2 (en) *	2009-08-05	2014-08-26	Panmira Pharmaceuticals, Llc	DP2 antagonist and uses thereof
JP2011057661A (ja)	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類
EP2496589B1 (en)	2009-11-05	2014-03-05	Boehringer Ingelheim International GmbH	Novel chiral phosphorus ligands
JP2013517272A (ja)	2010-01-15	2013-05-16	メルク・シャープ・エンド・ドーム・コーポレイション	抗糖尿病化合物としてのオキサジアゾール・ベータ・カルボリン誘導体
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013531636A (ja)	2010-05-26	2013-08-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体
EP2397473A1 (en)	2010-06-14	2011-12-21	LEK Pharmaceuticals d.d.	A stable highly crystalline anacetrapib
EP2582698B1 (en)	2010-06-16	2016-09-14	Vitae Pharmaceuticals, Inc.	Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en)	2010-06-25	2011-12-29	Boehringer Ingelheim International Gmbh	Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
US20130225618A1 (en)	2010-10-04	2013-08-29	Kowa Co., Ltd.	Agent for inhibiting expression of lipid metabolism related mrna
CN103269592B (zh)	2010-10-29	2016-05-11	默沙东公司	环胺取代的噁唑烷酮cetp抑制剂
CN103179960A (zh)	2010-11-02	2013-06-26	贝林格尔.英格海姆国际有限公司	治疗代谢疾病的药物组合
EP2468736A1 (en) *	2010-12-23	2012-06-27	LEK Pharmaceuticals d.d.	Synthesis of intermediates for preparing anacetrapib and derivates thereof
EP2468735A1 (en) *	2010-12-23	2012-06-27	LEK Pharmaceuticals d.d.	Synthesis of intermediates for preparing anacetrapib and derivates thereof
WO2012101142A1 (en)	2011-01-26	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for assessing a subject's risk of having a cardiovascular disease.
CN105001219A (zh)	2011-02-25	2015-10-28	默沙东公司	用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
WO2012141487A2 (en)	2011-04-12	2012-10-18	Chong Kun Dang Pharmaceutical Corp.	Cycloalkenyl aryl derivatives for cetp inhibitor
WO2013005834A1 (ja) *	2011-07-07	2013-01-10	持田製薬株式会社	高純度ｅｐａを含有する抗肥満剤
SG10201605304VA (en)	2011-07-08	2016-08-30	Novartis Ag	Method of treating atherosclerosis in high triglyceride subjects
JO3210B1 (ar)	2011-10-28	2018-03-08	Merck Sharp & Dohme	مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
US9145348B2 (en) *	2011-10-31	2015-09-29	Merck Sharpe & Dohme Corp.	Process for synthesizing a CETP inhibitor
WO2013064188A1 (en)	2011-11-03	2013-05-10	Lek Pharmaceuticals D.D.	A stable highly crystalline anacetrapib
EP2789347A4 (en)	2011-11-29	2015-12-16	Kowa Co	MEANS TO INHIBIT THE EXPRESSION OF NPC1L1 AND / OR LIPG-MRNA AND MEDICAMENTS FOR THE PREVENTION AND / OR TREATMENT OF ADIPOSITAS
MX352611B (es) *	2011-11-30	2017-11-29	Dae Woong Pharma	Composicion farmaceutica para evitar o tratar hipertrigliceridemia o enfermedades asociadas con hipertrigliceridemia.
WO2013091696A1 (en) *	2011-12-21	2013-06-27	Lek Pharmaceuticals D.D.	Synthesis of intermediates for preparing anacetrapib and derivatives thereof
US9353101B2 (en)	2012-05-02	2016-05-31	Merck Sharp & Dohme Corp.	Cyclic amine substituted heterocyclic CETP inhibitors
MX347400B (es)	2012-06-29	2017-04-18	Univ Nac Autónoma De México	Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
WO2014012428A1 (zh) *	2012-07-19	2014-01-23	上海恒瑞医药有限公司	噁唑烷酮类衍生物、其制备方法及其在医药上的应用
WO2014031465A1 (en)	2012-08-22	2014-02-27	Merck Sharp & Dohme Corp.	Novel azabenzimidazole tetrahydropyran derivatives
EP2934518B1 (en)	2012-12-19	2020-02-19	Merck Sharp & Dohme Corp.	Spirocyclic cetp inhibitors
WO2014099834A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Therapeutic thiazolidinone compounds
WO2014111953A1 (en) *	2013-01-17	2014-07-24	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Process for preparation of anacetrapib and intermediates thereof
US9493430B2 (en)	2013-01-31	2016-11-15	Chong Kun Dang Pharmaceutical Corp.	Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
US9981970B2 (en)	2013-07-30	2018-05-29	Merck Sharp & Dohme Corp.	Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors
EP3054945B1 (en)	2013-10-10	2018-08-15	Merck Sharp & Dohme Corp.	3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein
CN105814064A (zh)	2013-12-17	2016-07-27	默沙东公司	作为胆固醇酯转运蛋白的抑制剂的稠合双环异噁唑啉类
WO2015106674A1 (zh) *	2014-01-14	2015-07-23	杭州普晒医药科技有限公司	一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
CN103923030B (zh) *	2014-03-27	2015-07-22	汕头经济特区鮀滨制药厂	一种安塞曲匹的关键中间体的合成方法
CN103923031A (zh) *	2014-04-01	2014-07-16	汕头经济特区鮀滨制药厂	一种安塞曲匹的中间体的合成方法
WO2016018729A1 (en) *	2014-07-29	2016-02-04	Merck Sharp & Dohme Corp.	Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
EP3795695A1 (en)	2014-07-30	2021-03-24	F. Hoffmann-La Roche AG	Genetic markers for predicting responsiveness to therapy
CN104230835B (zh) *	2014-09-01	2017-01-25	福建师范大学	一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
WO2016067194A1 (en) *	2014-10-27	2016-05-06	Sun Pharmaceutical Industries Limited	Process for the preparation of anacetrapib and an intermediate thereof
CN106032362B (zh) *	2015-03-10	2018-06-19	湖南千金湘江药业股份有限公司	安塞曲匹的制备方法
AU2017287919A1 (en)	2016-06-29	2019-01-17	Orion Corporation	Benzodioxane derivatives and their pharmaceutical use
KR101902002B1 (ko) *	2016-07-19	2018-09-27	재단법인 대구경북첨단의료산업진흥재단	Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
CN109563019A (zh) *	2016-08-17	2019-04-02	诺华股份有限公司	Nep抑制剂合成的新方法和中间体
CN106496154A (zh) *	2016-10-18	2017-03-15	湖南德魅信息技术有限公司	安塞曲匹的制备方法
CN106496211A (zh) *	2016-10-18	2017-03-15	湖南德魅信息技术有限公司	二氟甲基取代的噁唑烷酮化合物及其用途
CN106749075A (zh) *	2016-11-24	2017-05-31	山东新华制药股份有限公司	阿那曲波的恶唑烷酮中间体的晶型及其制备方法
US20190070178A1 (en)	2017-08-29	2019-03-07	Dalcor Pharma Uk Ltd., Stockport Zug Branch	Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
JOP20180092A1 (ar)	2017-10-13	2019-04-13	Gilead Sciences Inc	مثبطات hiv بروتياز
MX2021001520A (es)	2018-08-09	2021-05-27	Dalcor Pharma Uk Ltd Leatherhead Zug Branch	Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
WO2020178443A1 (en)	2019-03-07	2020-09-10	Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch	Methods for treating or preventing heart failure and reducing risk of heart failure
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
CA3148300A1 (en)	2019-07-19	2021-01-28	Biosynth Ag	Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
KR102698413B1 (ko)	2020-05-05	2024-08-26	뉴베일런트, 아이엔씨.	헤테로방향족 거대환식 에터 화학치료제
CA3179700A1 (en)	2020-05-05	2021-11-11	Nuvalent, Inc.	Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2022075645A1 (ko) *	2020-10-08	2022-04-14	재단법인 대구경북첨단의료산업진흥재단	Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
EP4362933A4 (en) *	2021-06-30	2025-06-04	Apellis Pharmaceuticals, Inc.	COMPLEMENT INHIBITION
WO2023056405A1 (en)	2021-10-01	2023-04-06	Nuvalent, Inc.	Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2025093129A1 (en)	2023-11-01	2025-05-08	Newamsterdam Pharma B.V.	Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179442A (en) *	1975-08-29	1979-12-18	York Hartleben	4-(Alpha-hydroxy-isopropyl)-5-phenyl-oxazolidin-2-one
DE2655369A1 (de) *	1976-12-03	1978-06-08	Schering Ag	5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
US4851423A (en)	1986-12-10	1989-07-25	Schering Corporation	Pharmaceutically active compounds
WO1988009661A1 (en) *	1987-06-10	1988-12-15	Pfizer Inc.	Oxazolidin-2-one derivatives as hypoglycemic agents
EP0605729B1 (en) *	1992-04-30	2000-07-26	Taiho Pharmaceutical Co., Ltd.	Oxazolidine derivative and pharmaceutically acceptable salt thereof
KR950704278A (ko) *	1992-10-15	1995-11-17	시오노 요시히꼬	세포내 포스포리파제 a₂저해 활성을 갖는 옥사졸리논 유도체(oxazolinone derivative having intracellular phospholipase a₂inhibitor activity)
US5482971A (en) *	1993-10-01	1996-01-09	American Cyanamid Company	Beta3 -adrenergic agents and their use in pharmaceutical compositions
ATE255413T1 (de) *	1994-04-21	2003-12-15	Schering Ag	Pde iv-inhibitoren zur behandlung der multiplen sklerose
FR2729954B1 (fr) *	1995-01-30	1997-08-01	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1996024350A1 (de) *	1995-02-10	1996-08-15	Schering Aktiengesellschaft	Pharmazeutische präparate zur tnf-inhibition
WO1996036616A1 (en) *	1995-05-17	1996-11-21	E.I. Du Pont De Nemours And Company	Fungicidal cyclic amides
US5612363A (en)	1995-06-02	1997-03-18	Berlex Laboratories, Inc.	N,N-di(aryl) cyclic urea derivatives as anti-coagulants
BR9609001A (pt)	1995-06-20	1999-06-29	Du Pont	Método para controle de artrópodes composto composicão fungicida e método para controlar doencas de planta
US5846990A (en) *	1995-07-24	1998-12-08	Bristol-Myers Squibb Co.	Substituted biphenyl isoxazole sulfonamides
US6310095B1 (en) *	1995-11-06	2001-10-30	University Of Pittsburgh	Inhibitors of protein isoprenyl transferases
AU1856997A (en)	1996-02-02	1997-08-22	Merck & Co., Inc.	Method for raising hdl cholesterol levels
DE19647380A1 (de) *	1996-11-15	1998-05-20	Hoechst Ag	5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998023155A1 (en)	1996-11-26	1998-06-04	E.I. Du Pont De Nemours And Company	Arthropodicidal and fungicidal cyclic amides
DE19704243A1 (de) *	1997-02-05	1998-08-06	Bayer Ag	Neue 2-Amino-substituierte Pyridine
EP0966447B1 (en) *	1997-03-03	2003-03-05	Boehringer Ingelheim Pharmaceuticals Inc.	Small molecules useful in the treatment of inflammatory disease
CA2288330C (en)	1997-05-07	2014-02-11	University Of Pittsburgh	Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
DE19741400A1 (de) *	1997-09-19	1999-03-25	Bayer Ag	Benzyl-biphenyle
JP2002501059A (ja)	1998-01-23	2002-01-15	ファルマシア・アンド・アップジョン・カンパニー	オキサゾリジノンの組合せライブラリー、組成物および調製方法
DE19816880A1 (de) *	1998-04-17	1999-10-21	Boehringer Ingelheim Pharma	Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
GT199900147A (es)	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU780787B2 (en)	1999-09-17	2005-04-14	Millennium Pharmaceuticals, Inc.	Benzamides and related inhibitors of factor Xa
HN2000000203A (es) *	1999-11-30	2001-06-13	Pfizer Prod Inc	Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US6462063B1 (en)	2000-02-04	2002-10-08	Fibrogen, Inc.	C-proteinase inhibitors
US6762200B2 (en)	2000-03-28	2004-07-13	Nippon Soda Co. Ltd.	Oxa(thia)zolidine derivative and anti-inflammatory drug
PL362379A1 (en) *	2000-12-21	2004-10-18	Aventis Pharma Deutschland Gmbh	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
HUP0401005A3 (en)	2001-09-11	2007-11-28	Astrazeneca Ab	Oxazolidinone and/or isoxazoline antibacterials, process for their preparation, their use and pharmaceutical compositions containing them
AU2002335015B8 (en)	2001-10-16	2006-11-30	Memory Pharmaceuticals Corporation	4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AR043050A1 (es) *	2002-09-26	2005-07-13	Rib X Pharmaceuticals Inc	Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
AU2004222434B2 (en)	2003-03-17	2010-06-03	Japan Tobacco Inc.	Pharmaceutical compositions of CETP inhibitors
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
DOP2005000123A (es) *	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
CN101180288A (zh)	2005-03-31	2008-05-14	科学与工业研究会	与抗感染药物联用的芳香族取代的戊二烯酸酰胺
US7910592B2 (en) *	2005-12-30	2011-03-22	Merck Sharp & Dohme Corp.	CETP inhibitors
JP5040036B2 (ja) *	2005-12-30	2012-10-03	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体
JP5199121B2 (ja) *	2005-12-30	2013-05-15	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｅｔｐ阻害剤

2005
- 2005-01-31 DO DO2005000123A patent/DOP2005000123A/es unknown
- 2005-06-23 MY MYPI20052868A patent/MY167430A/en unknown
- 2005-06-26 JO JOP/2005/0091A patent/JO2994B1/ar active
- 2005-06-28 GT GT200500175A patent/GT200500175A/es unknown
- 2005-06-30 PE PE2005000763A patent/PE20060525A1/es active IP Right Grant
- 2005-06-30 TW TW094122197A patent/TWI299991B/zh not_active IP Right Cessation
- 2005-06-30 PA PA20058638101A patent/PA8638101A1/es unknown
- 2005-07-01 AU AU2005270058A patent/AU2005270058B2/en not_active Ceased
- 2005-07-01 EA EA200700259A patent/EA011130B1/ru not_active IP Right Cessation
- 2005-07-01 AR ARP050102755A patent/AR049956A1/es not_active Application Discontinuation
- 2005-07-01 RS RS20120497A patent/RS52563B/sr unknown
- 2005-07-01 HR HRP20120993TT patent/HRP20120993T1/hr unknown
- 2005-07-01 CN CN201410720703.1A patent/CN104447603A/zh active Pending
- 2005-07-01 DK DK05771445.3T patent/DK1765793T3/da active
- 2005-07-01 CN CN201110245073.3A patent/CN102304096B/zh not_active Expired - Fee Related
- 2005-07-01 BR BRPI0512910-9A patent/BRPI0512910A/pt not_active Application Discontinuation
- 2005-07-01 JP JP2007519533A patent/JP4695139B2/ja not_active Expired - Fee Related
- 2005-07-01 SI SI200531643T patent/SI1765793T1/sl unknown
- 2005-07-01 CA CA2570717A patent/CA2570717C/en not_active Expired - Fee Related
- 2005-07-01 US US11/173,295 patent/US7652049B2/en active Active
- 2005-07-01 EP EP11184420A patent/EP2415759A1/en not_active Withdrawn
- 2005-07-01 KR KR1020077000039A patent/KR101204336B1/ko not_active Expired - Fee Related
- 2005-07-01 MX MX2007000035A patent/MX2007000035A/es active IP Right Grant
- 2005-07-01 WO PCT/US2005/023775 patent/WO2006014413A1/en not_active Ceased
- 2005-07-01 PT PT57714453T patent/PT1765793E/pt unknown
- 2005-07-01 US US11/631,821 patent/US20080119476A1/en not_active Abandoned
- 2005-07-01 NZ NZ552061A patent/NZ552061A/en not_active IP Right Cessation
- 2005-07-01 PL PL05771445T patent/PL1765793T3/pl unknown
- 2005-07-01 GE GEAP20059837A patent/GEP20094694B/en unknown
- 2005-07-01 CN CN201110245074.8A patent/CN102311401B/zh not_active Expired - Fee Related
- 2005-07-01 WO PCT/US2005/023546 patent/WO2006014357A1/en not_active Ceased
- 2005-07-01 ES ES05771445T patent/ES2393721T3/es not_active Expired - Lifetime
- 2005-07-01 CN CN201410720701.2A patent/CN104557757A/zh active Pending
- 2005-07-01 EP EP05771445A patent/EP1765793B1/en not_active Expired - Lifetime
- 2005-07-01 SV SV2005002160A patent/SV2007002160A/es unknown
2006
- 2006-12-13 CR CR8808A patent/CR8808A/es unknown
- 2006-12-22 NI NI200600322A patent/NI200600322A/es unknown
- 2006-12-28 EC EC2006007124A patent/ECSP067124A/es unknown
- 2006-12-28 IL IL180432A patent/IL180432A/en not_active IP Right Cessation
2007
- 2007-01-03 EG EGNA2007000001 patent/EG27138A/xx active
- 2007-02-01 MA MA29647A patent/MA28780B1/fr unknown
- 2007-02-01 NO NO20070607A patent/NO339808B1/no not_active IP Right Cessation
2009
- 2009-11-25 US US12/625,783 patent/US8735435B2/en active Active
2010
- 2010-02-16 JP JP2010031195A patent/JP4491062B1/ja not_active Expired - Fee Related
2011
- 2011-01-27 JP JP2011015653A patent/JP5543932B2/ja not_active Expired - Fee Related
2012
- 2012-01-12 IL IL217530A patent/IL217530A0/en unknown
- 2012-07-30 AR ARP120102770A patent/AR087382A2/es unknown
- 2012-12-21 CY CY20121101259T patent/CY1117930T1/el unknown
2014
- 2014-04-14 US US14/252,256 patent/US20140221383A1/en not_active Abandoned
2015
- 2015-10-05 US US14/875,438 patent/US20160075724A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104447603A (zh)	2015-03-25
TW200605884A (en)	2006-02-16
BRPI0512910A (pt)	2008-04-15
NO339808B1 (no)	2017-02-06
US8735435B2 (en)	2014-05-27
MY167430A (en)	2018-08-28
JP4491062B1 (ja)	2010-06-30
AU2005270058B2 (en)	2009-04-23
EP1765793B1 (en)	2012-09-26
DOP2005000123A (es)	2011-07-15
TWI299991B (en)	2008-08-21
JP4695139B2 (ja)	2011-06-08
HRP20120993T1 (hr)	2012-12-31
CA2570717C (en)	2011-09-13
JO2994B1 (ar)	2016-09-05
CN104557757A (zh)	2015-04-29
US7652049B2 (en)	2010-01-26
RS52563B (sr)	2013-04-30
SI1765793T1 (sl)	2013-05-31
JP5543932B2 (ja)	2014-07-09
SV2007002160A (es)	2007-03-20
PT1765793E (pt)	2012-12-06
CN102304096A (zh)	2012-01-04
CY1117930T1 (el)	2017-05-17
JP2008505120A (ja)	2008-02-21
EA200700259A1 (ru)	2007-08-31
CN102311401A (zh)	2012-01-11
ES2393721T3 (es)	2012-12-27
NO20070607L (no)	2007-04-02
US20100099716A1 (en)	2010-04-22
AR087382A2 (es)	2014-03-19
GEP20094694B (en)	2009-05-25
EA011130B1 (ru)	2008-12-30
ECSP067124A (es)	2007-01-26
US20140221383A1 (en)	2014-08-07
IL180432A0 (en)	2007-06-03
CN102311401B (zh)	2014-12-03
WO2006014413A1 (en)	2006-02-09
NI200600322A (es)	2007-08-07
GT200500175A (es)	2006-03-14
MX2007000035A (es)	2007-03-07
CN102304096B (zh)	2014-12-03
AR049956A1 (es)	2006-09-20
EG27138A (en)	2015-08-09
NZ552061A (en)	2010-09-30
KR20070039523A (ko)	2007-04-12
JP2011137006A (ja)	2011-07-14
JP2010150269A (ja)	2010-07-08
IL217530A0 (en)	2012-02-29
KR101204336B1 (ko)	2012-11-27
EP1765793A1 (en)	2007-03-28
AU2005270058A1 (en)	2006-02-09
US20080119476A1 (en)	2008-05-22
CA2570717A1 (en)	2006-02-09
EP2415759A1 (en)	2012-02-08
PA8638101A1 (es)	2006-03-24
IL180432A (en)	2012-02-29
MA28780B1 (fr)	2007-08-01
PL1765793T3 (pl)	2013-03-29
WO2006014357A1 (en)	2006-02-09
CR8808A (es)	2007-08-28
US20060040999A1 (en)	2006-02-23
US20160075724A1 (en)	2016-03-17
PE20060525A1 (es)	2006-07-13

Publication	Publication Date	Title
DK1765793T3 (da)	2013-01-14	Anacetrapib og andre cetp-inhibitorer
NO2017017I1 (no)	2017-05-04	umeklinidium og vilanterol
DK1592686T3 (da)	2009-10-19	Gyrase-inhibitorer og anvendelser deraf
NO20081604L (no)	2008-07-03	Nitrogeninneholdende heterocyklisk forbindelse og farmasøytisk anvendelse derav
NO20054453L (no)	2005-11-29	P38 inhibitorer og fremgangsmater for anvendelse derav
EP1737811A4 (en)	2009-06-17	CETP INHIBITORS
ATE423121T1 (de)	2009-03-15	Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
EP1973889A4 (en)	2011-06-15	Cetp inhibitors
EP1943080A4 (en)	2012-09-12	METHOD AND APPARATUS FOR BLOW MOLDING WITH STRETCHING
DK1711181T3 (da)	2010-02-01	Quinolin-derivater og anvendelse af disse som mycobakterielle inhibitorer
DK1997809T3 (da)	2014-07-21	P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK1871418T3 (da)	2014-06-10	Humaniserede anti-cd70-bindende midler og anvendelser deraf
DE602005020560D1 (de)	2010-05-27	Finger-Identifikationsverfahren und -vorrichtung
DK1725253T3 (da)	2014-07-07	Medikamenter og fremgangsmåder til behandling af hovedpine
EP1653970A4 (en)	2008-10-15	GSK-3 HEMMER AND ITS USES
DK2253614T3 (da)	2013-01-07	IAP-inhibitorer
EP1804888A4 (en)	2012-11-07	BARIATRIC DEVICE AND METHOD
NO20040640L (no)	2004-08-16	Anordning og fremgangsmate
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DE602004018837D1 (de)	2009-02-12	Ptidase-iv-inhibitoren
EP1848377A4 (en)	2009-12-30	APPARATUS AND METHOD FOR ARTHROPLASTY OF THE SHOULDER
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
DK1817055T3 (da)	2013-04-08	Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DE602005023261D1 (de)	2010-10-14	Duale Speichervorrichtung und Verfahren dergleichen
NO20044012D0 (no)	2004-09-23	Fremgangsmate og et system